KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation and Depletion: 2009-2024

Historic Depreciation and Depletion for Emergent BioSolutions (EBS) over the last 11 years, with Dec 2024 value amounting to $43.7 million.

  • Emergent BioSolutions' Depreciation and Depletion fell 29.70% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year decrease of 29.96%. This contributed to the annual value of $43.7 million for FY2024, which is 26.55% down from last year.
  • Emergent BioSolutions' Depreciation and Depletion amounted to $43.7 million in FY2024, which was down 26.55% from $59.5 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Depreciation and Depletion ranged from a high of $83.4 million in FY2022 and a low of $43.7 million during FY2024.
  • Moreover, its 3-year median value for Depreciation and Depletion was $59.5 million (2023), whereas its average is $62.2 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 34.08% in 2022, then dropped by 28.66% in 2023.
  • Emergent BioSolutions' Depreciation and Depletion (Yearly) stood at $50.1 million in 2020, then rose by 24.15% to $62.2 million in 2021, then spiked by 34.08% to $83.4 million in 2022, then fell by 28.66% to $59.5 million in 2023, then fell by 26.55% to $43.7 million in 2024.